project id: TCGA-BLCA; case submitter id: TCGA-FD-A3N6; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.0; rna integrity number: 8.3; age at index: 43; days to birth: -15758; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1968; age at diagnosis: 15758; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 851.0; icd 10 code: C67.3; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Anterior wall of bladder; synchronous malignancy: No; tissue or organ of origin: Anterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 0.4520547945205479; pack years smoked: 8.25; is ffpe: false; composition: Not Reported; days to collection: 181; days to sample procurement: 0; initial weight: 280.0; portion submitter id: TCGA-FD-A3N6-01A-11; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 5.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 20.0; percent tumor cells: 75.0; percent tumor nuclei: 75.0;